Immunogen (IMGN) Releases Quarterly Earnings, Beats Estimates By $0.10 EPS
Immunogen (NASDAQ:IMGN) released its earnings data on Friday. The company reported ($0.13) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.23) by $0.10, Analyst Ratings.Net reports. The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $12.10 million. During the same quarter last year, the company posted ($0.30) earnings per share. Immunogen’s revenue was up 319.5% compared to the same quarter last year.
A number of research firms have recently commented on IMGN. Analysts at Chardan Capital initiated coverage on shares of Immunogen in a research note to investors on Monday, September 30th. They set a “buy” rating and a $21.00 price target on the stock. On a related note, analysts at Jefferies Group reiterated a “buy” rating on shares of Immunogen in a research note to investors on Monday, September 9th. They now have a $21.00 price target on the stock. Finally, analysts at Leerink Swann initiated coverage on shares of Immunogen in a research note to investors on Wednesday, September 4th. They set an “outperform” rating and a $24.00 price target on the stock. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Immunogen currently has a consensus rating of “Buy” and a consensus target price of $18.80.
Immunogen (NASDAQ:IMGN) opened at 17.25 on Friday. Immunogen has a 1-year low of $10.85 and a 1-year high of $20.25. The stock has a 50-day moving average of $17.1 and a 200-day moving average of $16.69. The company’s market cap is $1.468 billion.
ImmunoGen, Inc (NASDAQ:IMGN) develops targeted, antibody-based therapeutics for the treatment of cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.